Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 0.59 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | BLVRB | P30043 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR5A | P47898 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12388484 | 0.81 | TTR (0.50) | TTRMYCACMSDMAOABLVRB | |
| SCHEMBL2745957 | 0.78 | TTR (0.50) | TTRACMSDMAOABLVRBHDAC6 | |
| SCHEMBL16689869 | 0.77 | ACHE (0.46) | DHODHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9907578 | 0.77 | LMNA (0.43) | TTRDHODHLMNASMN1; SMN2HTR5A | |
| SCHEMBL28015624 | 0.76 | TTR (0.59) | TTRMYCACMSDDHODHNPC1 | |
| SCHEMBL13601575 | 0.76 | TTR (0.59) | TTRMYCDHODHCES2CES1 | |
| SCHEMBL13601660 | 0.75 | TTR (0.54) | TTRMYCRAB9ALMNA | |
| SCHEMBL1712674 | 0.75 | TTR (0.88) | TTRLMNASMN1; SMN2 | |
| SCHEMBL6564894 | 0.75 | TTR (0.54) | TTRMYCLMNASMN1; SMN2TPMT | |
| SCHEMBL8047467 | 0.74 | TPMT (0.59) | TTRMYCLMNASMN1; SMN2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131090-A1 | AMINO ACID COMPOUND | 旭化成ファーマ株式会社 (JP) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | TTR 2102/4885MYC 3353/4885ACMSD 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.